首页/数据集/Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

NCATS Open Data2024-08-16 更新2026-08-08 收录

疫苗临床试验

疫苗免疫原性与安全性评估

数据链接：

https://doi.org/10.1093/infdis/jiad508 数据链接链接失效反馈

官方服务：

资源简介：

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

应用场景：

创建时间：

2023-11-16

疫苗临床试验

免疫反应

Background: Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placeb

DataONE2014-12-22 更新160

ATN 064 Burk HPV DNA Dataset in Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women

疫苗临床试验

HIV感染者免疫干预

Burk Lab HPV DNA data Study Description A Phase II, open-label, multi-center study that evaluated the immunogenicity, safety, tolerability, and behavioral impact of an HPV-6, -11, -16, -18 vaccine in

NIAID Data Ecosystem40

Dataset from Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants

疫苗临床试验

结核病预防

This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme

NIAID Data Ecosystem20

DataSheet_1_Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.docx

癌症免疫治疗

疫苗临床试验

BackgroundImmune checkpoint blockade with monoclonal antibodies targeting programmed death 1 (PD-1) and its ligand PD-L1 has played a major role in the rise of cancer immune therapy. We have identifie

NIAID Data Ecosystem70

Characteristics of HVTN 502 and 503 trial participants.

疫苗临床试验

免疫基因型分析

Data shown are median values (interquartile range) unless otherwise indicated. * At time of sampling § HLA-B*27, B51, B*5701/03, B*5801 and B*8101 Characteristics of HVTN 502 and 503 trial participant

NIAID Data Ecosystem20

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

资源简介：

相关数据集